全部资讯｜CELL INTELLIGENCE

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma.

PubMed 2026/04/30 发表Front ImmunolQ1 · IF 7（JCR 2025）

Epstein-Barr virus-positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop.

PubMed 2025/07/11 发表Am J Clin PatholQ2 · IF 2.3（JCR 2025）

EBV+ T 细胞和 NK 细胞 LPDs 的诊断复杂，需结合临床信息及形态学和分子特征的多参数方法。

T cell malignancies after CAR T cell therapy in the DESCAR-T registry.

PubMed 2025/01/08 发表Nat MedQ1 · IF 52.5（JCR 2025）

Broadening the horizon: potential applications of CAR-T cells beyond current indications.

PubMed 2023/11/27 发表Front ImmunolQ1 · IF 7（JCR 2025）

AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.

PubMed 2022/07/18 发表Leuk LymphomaQ3 · IF 2.1（JCR 2025）

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

PubMed 2022/05/06 发表Front OncolQ2 · IF 3.4（JCR 2025）

Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.

PubMed 2021/10/25 发表Int J Mol SciQ1 · IF 5.6（JCR 2025）

全部资讯 7